BTLA agonist for mudulation of dendritic cells

The BTLA agonist addresses the imbalance in dendritic cell maturation and immune checkpoint signals by inhibiting dendritic cell maturation and enhancing regulatory T cell production, effectively treating autoimmune and inflammatory disorders by restoring immune balance.

WO2024243594A1PCT designated stage expired Publication Date: 2024-11-28ANAPTYSBIO INC
View PDF 17 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/031289
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-25
Filing Date
2024-05-28
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Current therapies fail to effectively modulate dendritic cell maturation and immune checkpoint signals, leading to chronic inflammatory conditions and autoimmune disorders due to imbalances in T cell activity, where elevated levels of mature dendritic cells contribute to tissue damage and inflammation.

Method used

Administration of a BTLA agonist to patients, which binds to BTLA on T cells, dendritic cells, and other immune cells, inhibiting dendritic cell maturation, reducing T cell proliferation, and enhancing regulatory T cell production, thereby restoring immune balance.

Benefits of technology

The BTLA agonist effectively decreases mature dendritic cell levels, reduces inflammatory cytokine secretion, and increases regulatory T cell production, providing therapeutic benefits for autoimmune and inflammatory disorders by modulating the immune response.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024031289_28112024_PF_FP_ABST
    Figure US2024031289_28112024_PF_FP_ABST
Patent Text Reader

Abstract

Use of a BTLA agonist to modulate dendritic cell activation and maturation, and for the selection of patients for therapy for a BTLA agonist, and for monitoring the treatment with a BTLA agonist.
Need to check novelty before this filing date? Find Prior Art

Description

BTLA AGONIST FOR MODULATION OF DENDRITIC CELLSCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. provisional patent application no. 63 / 504,412 filed May 25, 2023, the entire disclosure of which is hereby incorporated by reference.INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ELECTRONICALLY

[0002] Incorporated by reference in its entirety herein is a computer-readable nucleotide / amino acid sequence listing submitted concurrently herewith and identified as follows: One 339,806 Byte ASCII (Text) file named "771156_ST.26.xml," created on May 20, 2024.BACKGROUND OF THE INVENTION

[0003] Tlymphocytes are activated from a naive state by a combination of T cell receptor (TCR) engagement and positive signals coming from costimulatory molecules. Conversely, coinhibitory molecules play important roles in modulating T cell activity by delivering negative signals to counter balance positive costimulatory signals. Coinhibitory molecules act as checkpoints to maintain immunologic tolerance to self and to control activated T cells after resolving immune insults such as infections and inflammation.

[0004] CD28 is the dominant costimulatory molecule on T cells that, once engaged with the ligands B7.1 or B7.2 on the surface of antigen-presenting cells (APC), delivers intracellular signals that enhance T cell proliferation and differentiation with concomitant TCR engagement. T cell proliferation and effector functions are inhibited when the same ligands engage the coinhibitory molecule cytotoxic T lymphocyte antigen-4 (CTLA-4) on T cells (Chambers et al., Ann. Rev. Immunol., 19:565-594, 2001; Egen et al., Nature Immunol., 3:611-618, 2002). Similarly, T cell proliferation and effector functions are inhibited when cells expressing PD-L1 engage the coinhibitory molecule PD-1 on T cells (Carter et al. Eur J Immunol., 32:634-43, 2002).

[0005] Dysfunction in negative checkpoint signals can contribute to chronic inflammatory conditions by preventing the suppressive signals that normally control autoreactive B and Tlymphocytes. In patients with autoimmune disorders, the immune system reacts to normal body tissues as if they were foreign and tissues can become infiltrated with activated T cells and B cells that have broken tolerance to self-antigens. As a consequence, the autoimmune T and B lymphocytes mediate inflammation and tissue damage. Lymphocytes expressing coinhibitory molecules such as B and T lymphocyte attenuator (BTLA), cytotoxic T lymphocyte antigen-4 (CTLA-4), and PD-1 are normally suppressed by other immune or non-immune cells in the tissues that express the corresponding ligands.

[0006] Knock-out of coinhibitory molecules or pharmacologic blockade of the coinhibitory interactions has been shown to release the suppressive breaks and induce expansion of tumorspecific T cell populations and direct them to attack and kill tumor cells in animal models of various cancers. Mice with BTLA knock-out have increased sensitivity to experimental autoimmune encephalomyelitis (Watanabe et al., Nat. Immunol., 4:670-679, 2003). Conversely, agonist antibodies targeting mouse BTLA have been shown to suppress T cell activity and have demonstrated efficacy in mouse models of graft versus-host disease (GvHD) (Albring et al., J. Exp. Med., 207: 2551-2559, 2010).

[0007] The ligand for BTLA is the Herpes virus entry mediator (HVEM), also known as tumor necrosis factor receptor superfamily member 14 (TNFRSF14). HVEM is also a positive costimulatory molecule that binds two secreted growth factors, lymphotoxin alpha and LIGHT, and is also used by herpes simplex virus (HSV) for entry into cells. Engagement of BTLA on T cells by HVEM expressed on tumor cells or other immune cells results in negative, suppressive signals. Anti-BTLA antibodies that bind and agonize BTLA could induce direct negative signals similar to that delivered by the native ligand HVEM thereby suppressing autoreactive T cell and B cells responses in autoimmune and inflammatory diseases. Furthermore, agonist antibodies that engage BTLA without interfering with the natural HVEM-BTLA interaction could enhance the natural coinhibitory signal.

[0008] Dendritic cells also play a major role in the inflammatory process. Dendritic cells are upstream coordinators of T-cell activation and can regulate T-cell priming and generation of inflammatory T-cells.

[0009] Thus, agents capable of binding BTLA are needed, especially those agents capable of modulating the immune checkpoint signals and / or modulating dendritic cell activity.BRIEF SUMMARY OF THE INVENTION

[0010] Provided herein is a method of modulating dendritic cell maturation, the mehod comprising administering a BTLA agonist to the patient. Also provided herein is a method of treating a condition associated with dendritic cell maturation, or a condition characterized by abnormally high levels of mature dendritic cells as compared to immature dendritic cells, the method comprising administering a BTLA agonist to the patient.

[0011] Also provided herein is a method of selecting a patient for treatment with a BTLA agonist, the method comprisisng determining the level of mature dendritic cells ina p atient or in a biological sample from the patient, and selecting the patient for treatment if the level of mature dendritic cells is elevated as compared to a control. Also provided herein is a method of monitoring the treating of a patient with a BTLA agonist, t he method comprising monitoring the level of mature dendritic cells in a patient or in a biological sample from a patient, wherin a decrease in the level of mature dendritic cells indicates that the patient is responding to the treatment with the BTLA agonist.

[0012] Also provided herein is a BTLA agonist for use in the inventive methods.BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S)

[0013] Figure 1 is a schematic illustration of the relationship between dendritic cell maturation, T-cell proliferation, and cytokine secretion. Mature dendritic cells in combination with naive T cells can stimulate inflammatory cytokine secretion. The BTLA agonist provided herein can inhibit DC maturation, activated T-cell proliferation, and inflammatory cytokine secretion.

[0014] Figures 2A-2B are graphs of % proliferating T-cells plotted against antibody concentration (Fig. 2A) and cell count in a carboxyfluorescein succinimidyl ester (CFSE) assay (Fig. 2B) after incubating atopic dermatitis (AD) patient-derived peripheral blood mononuclear cells (PBMCs) with BTLA agonist antibody.

[0015] Figures 3A-3D provides graphs showing that the BTLA agonist provided herein inhibits Thl, Th2,Thl7, and Th22 cytokine secretion in atopic dermatitis patient-derived PBMCs.

[0016] Figure 4 is a plot of CD11c, MHCII, and BTLA in lipopolysaccharide (LPS)- stimluated and mature dendritic cells, which illustrates that BTLA is highly expressed on mature dendritic cells.

[0017] Figure 5 is a schematic illustration of how the BTLA agonist provided herein modulates BTLA expression, reducing the number of mature dendritic cells, and therefore, reduces T-cell proliferation and cytokine secretion, and increases regulatory T-cells (Tregs).

[0018] Figures 6A-6D provides graphs demonstrating that the BTLA agonist provided herein inhibits DC maturation (Figs. 6A and 6B), reduces antigen presentation (Fig. 6C), and reduces expression of costimulatory molecules (Fig. 6D).

[0019] Figures 7A and 7B provide an illustration of how dendritic cells treated with a BTLA agonist provided herein induce functional Tregs restoring immune balance (Fig. 7 A), and provides a plot of expression of CD25 and Foxp3 demonstrating that BTLA agonist increases regulatory T-cells in a dendritice cell / T-cell co-culture (Fig. 7B).DETAILED DESCRIPTION OF THE INVENTION

[0020] BTLA is a 30 kilodalton (kD) type 1 transmembrane protein with an immunoglobulin-like extracellular domain, an immunoreceptor tyrosine-based inhibitory motif (ITIM), and an immunoreceptor tyrosine-based switch motif (ITSM). BTLA is expressed on B cells and T cells and acts a negative regulator of both B and T cell activity through interaction with its receptor, Herpes virus entry mediator (HVEM), expressed on tumor cells or APCs (Watanabe et al., Nat. Immunol., 4:670-679, 2003). A BTLA agonist binds to BTLA without preventing binding between BTLA and HVEM, and can even enhance binding between BTLA and HVEM.

[0021] BTLA also is expressed on dendritic cells. Without wishing to be bound by any particular theory or mechanism of action, it is believed that administration of a BTLA agonist as provided herein (e g., a BTLA-binding ageint as provided herein, such as 6G3), binds to BTLA on both T-cells / B-cells and dendritic cells. Furthermore, it is belived that binding of the BTLA agonist to dendritic cells inhibits or reduces dendritic cell maturation levels, which, in turn, reduces T-cell priming and proliferation and reduces cytokine secretion. This reduction in T-cell priming / proliferation and cytokine secretion is across Thl, Th2, Thl7, and Th22 cells.Furthermore, it is believed that binding of the BTLA agonist to dendritic cells increases the production of regulatory T-cells (Tregs), which express the transcription factor Foxp3 and suppress activation, proliferation and cytokine production of CD4+ and CD8+ T cells. And, it is believed that the BTLA agonist provided herein excerts these effects by reducing dendritic cell maturation in addition to regulating BTLA signaling on T-cells directly.

[0022] Accordingly, the present disclosure provides a method of modulating dendritic cell maturation, the method comprising administering a BTLA agonist to the patient. The patient can have a condition associated with increased maturation levels of dendritic cells. Thus, also provided is a method of treating a condition associated with dendritic cell maturation in a patient, or a condition characterized by abnormally high levels of mature dendritic cells as compared to immature dendtric cells in a patient, the method comprising administering a BTLA agonist to the patient. Also provided is a method of increasing the production of Tregs, the method comprising administering a BTLA agonist to a patient in need of increased Treg production (e.g., a patient with lower-than-normal Treg levels, or who would otherwise benefit from increased Treg production, such as by restoring immune balance).

[0023] Further provided herein is a method of selecting a patient for treatment with a BTLA agonist, the method comprising determining the level of mature dendritic cells in a patient or in a biological sample from the patient, and selecting the patient for treatment if the level of mature dendritic cells is elevated as compared to a control.

[0024] Also provided is a method of monitoring the treatment of a patient with a BTLA agonist, the method comprising monitoring the level of mature dendritic cells in a patient or in a biological sample from a patient, wherein a decrease in the level of mature dendritic cells indicates that the patient is responding to the treatment with the BTLA agonist. In a related aspect, the method of monitoring the treatment of a patient with a BTLA agonist can comprise monitoring the level of Tregs, wherein an increase in the level of Tregs indicates the patient is responding to treatment. In other embodiments, the method comprises comparing the level of dendritic cell maturation or the level of Tregs in a patient (or biological sample from a patient) at a first time point to that at a second time point. The first time point can be either before or after the BTLA agonist had been administered to the subject, whereas the second point is after administration of the BTLA agonist. For instance, dendritic cell maturation levels or Treg levelscan be measured at two or more time points after administration of the BTLA agonist and compared to evaluate the effect of the BTLA agonist over time, optionally with one or more additional intervening administrations of the BTLA binding agent. In this manner, treatment with a BTLA binding agent can be monitored.

[0025] In any of the foregoing methods, the level of dendritic cell maturation can be determined by any suitable method. For instance, the level of dendritic cell maturation can be measured in the patient, or a biological sample from the patient and compared to a control. The control can be, for instance, the level of mature dendritic cells in a non-diseased biological sample from the same patient; or the level of mature dendritic cells of another normal, nondiseased subject of the same type; or a reference level of mature dendritic cells established by the statistical analysis of the level of dendritic in a population of such normal, non-diseased subjects. The level of dendritic cell maturation can be determined by comparing the number of determining a ratio of the number of mature dendritic cells as compared to immature dendritic cells in a patient or biological sample from the patient. An increased level of dendritic cell maturation is a level (e.g., number of mature dendritic cells, or ratio of mature dendritic cells to immature dendritic cells) that is higher than the control, and a decreased level of dendritic cell maturation is a level (e.g., number of mature dendritic cells, or ratio of mature dendritic cells to immature dendritic cells) that is lower than the control.

[0026] The biological sample referred to in any of the foregoing methods can be a sample of any type of biological material from the patient, such as in vitro blood, plasma, serum, or tissue (e.g., skin tissue) sample from a patient.

[0027] The methods provided herein can be used in conjunction with the treatment of conditions associated with increased dendritic cell maturation, such as an immune response or inflammatory or autoimmune disorder associated with (e.g., caused by or characterized by) increased levels of mature dendritic cells. An “immune response” can entail, for example, antibody production and / or the activation of immune effector cells (e.g., T-cells), production of inflammatory cytokines, or any of the indications or disorders described herein or otherwise known in the art. As used herein, the terms “treatment,” “treating,” and the like refer to obtaining a desired pharmacologic and / or physiologic effect. Preferably, the effect is therapeutic, i.e., the effect partially or completely cures a disease and / or adverse symptomattributable to the disease. To this end, the inventive method comprises administering a “therapeutically effective amount” of the BTLA agonist. A “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic result. The therapeutically effective amount may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the BTLA agonist to elicit a desired response in the individual.

[0028] Alternatively, the pharmacologic and / or physiologic effect may be prophylactic, i.e., the effect completely or partially prevents a disease or symptom thereof. In this respect, the inventive method comprises administering a “prophylactically effective amount” of the BTLA agonist. A “prophylactically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired prophylactic result (e.g., prevention of disease onset).

[0029] Examples of inflammatory or autoimmune disorders include, for example, infections (viral, bacterial, fungal and parasitic), endotoxic shock associated with infection, arthritis, rheumatoid arthritis, asthma, Chronic obstructive pulmonary disease (COPD), pelvic inflammatory disease, Behcet disease, Alzheimer's Disease, inflammatory bowel disease including Crohn's disease and ulcerative colitis, Peyronie's Disease, coeliac disease, gallbladder disease, Pilonidal disease, peritonitis, psoriasis, psoriatic arthritis, vasculitis, antineutrophil cytoplasmic antibody-associated (ANCA) vasculitis, surgical adhesions, stroke, Type I Diabetes, lyme disease, arthritis, meningoencephalitis, autoimmune uveitis, immune mediated inflammatory disorders of the central and peripheral nervous system such as multiple sclerosis, lupus (such as systemic lupus erythematosus and chronic discoid lupus erythematosus) and Guillain-Barr syndrome, Atopic dermatitis, polymyositis, dermatomyositis, autoimmune hepatitis, fibrosing alveolitis, Grave's disease, IgA nephropathy, idiopathic thrombocytopenic purpura, Meniere's disease, pemphigus, pemphigoid, primary biliary cholangitis, hepatitis, sarcoidosis, scleroderma (localized scleroderma, systemic scleroderma, and progressive systemic scleroderma), Ganulomatosis with polyangiitis, other autoimmune disorders, cholangitis, pancreatitis, trauma (surgery), graft-versus-host disease, transplant rejection, heart disease including ischaemic diseases such as myocardial infarction as well as atherosclerosis, periarteritis nodosa (polyarteritis nodosa and microscopic poly angiitis), allergic granulomatousangiitis, hypersensitivity angiitis, aortitis syndrome (Takayasu arteritis), temporal arteritis, intravascular coagulation, bone resorption, osteoporosis, osteoarthritis, periodontitis and hypochlorhydia, Still's disease, Cogan's syndrome, RS3PE, polymyalgia rheumatica, fibromyalgia syndrome, antiphospholipid antibody syndrome, eosinophilic fasciitis, Guillain- Barre syndrome, myasthenia gravis, chronic atrophic gastritis, Goodpasture's syndrome, rapidly progressive glomerulonephritis, megaloblastic anemia, hemolytic anemia, autoimmune neutropenia, Hashimoto's thyroiditis, autoimmune adrenal insufficiency, primary hypothyroidism, idiopathic Addison's disease (chronic adrenal insufficiency), herpes gestationis, linear IgA bullous skin disease, epidermolysis bullosa acquisita, alopecia areata, vitiligo, Harada disease, autoimmune optic neuropathy, idiopathic azoospermia, recurrent fetal loss, or infertility related to lack of fetal-maternal tolerance.

[0030] In some embodiments, the disease or disorder is arthritis (e.g., rheumatoid arthritis or TNF-refractory rheumatoid arthritis), giant cell arteritis, polymyalgia rheumatica, primary Sjogren’s Syndrome, alopecia areata, primary biliary cholangitis (PBC), vitiligo, ANCA Vasculitis, Type 1 Diabetes, noninfectious uveitis psoriasis, graft vs. host disease (GvHD) or inflammatory bowel disease.

[0031] The methods provided herein are believed to be particularly useful for such diseases and disorders characterized by increased dendritic cell maturation levels.

[0032] As used herein, the terms “treatment,” “treating,” and the like refer to obtaining a desired pharmacologic and / or physiologic effect. Preferably, the effect is therapeutic, i.e., the effect partially or completely cures a disease and / or alleviates to any degree an adverse symptom attributable to the disease. To this end, the inventive method comprises administering a “therapeutically effective amount” of the BTLA agonist. A “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic result. The therapeutically effective amount may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the BTLA agonist to elicit a desired response in the individual. For example, a therapeutically effective amount of a BTLA agonist of the invention is an amount which increases BTLA bioactivity in a human.

[0033] Alternatively, the pharmacologic and / or physiologic effect may be prophylactic, i.e., the effect completely or partially prevents a disease or symptom thereof. In this respect, theinventive method comprises administering a “prophylactically effective amount” of the BTLA agonist. A “prophylactically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired prophylactic result (e.g., prevention of disease onset).

[0034] The BTLA agonist can be a BTLA-binding agent that comprises an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region, each of which comprise three complementarity determining regions (CDRs), usually referred to as CDR1, CDR2, or CDR3. The CDR regions also can be referred to using an “H” or “L” in the nomenclature to denote the heavy or light chain, respectively, i.e., CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, or CDRL3. The CDRs of a given Ig sequence can be determined by any of several conventional numbering schemes, such as Kabat, Chothia, Martin (Enhanced Chothia), IGMT, or AHo (these are commonly used names for numbering schemes widely known in the field and described in published literature see, e.g., Kabat, et al., Sequences of Proteins of Immunological Interest, U.S. Department of Health and Human Services, NIH (1991) describing the “Kabat” numbering scheme; Chothia, et al., Canonical Structures for the Hypervariable Regions of Immunoglobulins, J. Mol. Biol., 196:901-917 (1987) and Al-Lazikani et al., Standard Conformations for the Canonical Structures of Immunoglobulins, J. Mol. Biol., 273:927 - 948 (1997) describing the “Chothia” numbering scheme; Abhinandan et al., Analysis and Improvements to Kabat and Structurally Correct Numbering of Antibody Variable Domains, Mol. Immunol., 45: 3832 - 3839 (2008) describing the “Martin” or “Enhanced Chothia” numbering scheme; Lefranc et al., The IMGT unique numbering for immunoglobulins, T cell Receptors andlg-like domains, The Immunologist, 7: 132-136 (1999) and Lefranc et al., IMGT unique numbering for immunoglobulin and T cell receptor variable domains and I superfamily V-like domains, Dev. Comp. Immunol., 27: 55 - 77 (2003) describing the “IMGT” numbering scheme; and Honegger et al., Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool, J. Mol. Biol. 309: 657 - 670 (2001) describing the “AHo” numbering scheme). The BTLA-binding agents provided herein are manmade and non-naturally occurring. They have been generated by laboratory techniques and, thus, are properly considered recombinant or synthetic molecules comprising recombinant or synthetic amino acid sequences. The immunoglobulin heavy and light chain polypeptides can be“isolated” in the sense that they are removed from the environment in which they are produced (e.g., cell culture) and purified to any degree.

[0035] According to one aspect of the disclosure, the BTLA-binding agent comprises immunoglobulin heavy chain polypeptide of the BTLA-binding agent comprises the amino acid sequence of any one of SEQ ID NOs: 1-15, 207, 208, 217, or 218, or at least the CDRs thereof; or comprises an amino acid sequence with at least 80% sequence identity (e.g., at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) to any one of SEQ ID NOs 1- 15, 207, 208, 217, or 218. The CDRs can be as determined using any known numbering scheme, such as such as Kabat, Chothia, Martin (Enhanced Chothia), IGMT, or AHo. In some embodiments, CDR1, CDR2, and CDR3 comprise residues 31-35 (CDRH1), 50-66 (CDRH2), and 99-106 (CDRH3) of SEQ ID NOs: 1-15, 207, 208, 217, or 218.

[0036] In some embodiments, the immunoglobulin heavy chain comprises the following CDRs:(a) a CDRH1 comprising Asp Tyr Thr He His (SEQ ID NO: 27);(b) a CDRH2 comprising Trp He Tyr Pro Gly Ser Gly Asn Thr Lys Tyr Asn Asp Xaal Phe Lys Xaa2 (SEQID NO: 30), wherein Xaal is lysine (Lys) or glutamic acid (Glu), and Xaa2 is aspartic acid (Asp) or valine (Vai) (e.g., SEQ ID NO: 28, 30, 31, 212, or 222); and(c) a CDRH3 comprising Arg Xaal Xaa2 Tyr Xaa3 Met Xaa4 Tyr (SEQ ID NO: 32), wherein Xaal is asparagine (Asn) or serine (Ser), Xaa2 is tyrosine (Tyr) or histidine (His), Xaa3 is alanine (Ala) or valine (Vai), and Xaa4 is glutamic acid (Glu) or aspartic acid (Asp). Examples of such CDRH3 sequences include, for instance, SEQ ID NOs: 29, 33, 34, 213, or 223.

[0037] In some embodiments, the immunoglobulin heavy chain polypeptide comprises the amino acid sequence Gin Vai Gin Leu Vai Gin Ser Gly Ala Glu Vai Lys Lys Pro Gly Ala Ser Vai Lys Vai Ser Cys Lys Ala Ser Gly Xaal Thr Xaa2 Thr Asp Tyr Thr He His Trp Vai Arg Gin Ala Pro Gly Gin Arg Leu Glu Trp Met Gly Trp lie Tyr Pro Gly Ser Gly Asn Thr Lys Tyr Asn Asp Xaa3 Phe Lys Xaa4 Arg Vai Thr He Thr Xaa5 Asp Xaa6 Ser Xaa7 Xaa8 Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Vai Tyr Xaa9 Cys Ala Arg Arg XaalO Xaal 1 TyrXaal2 Met Xaal3 Tyr Trp Gly Gin Gly Thr Thr Vai Thr Vai Ser Ser Ala (SEQ ID NO: 26), or at least the CDR regions thereof, whereinXaal is phenylalanine (Phe) or tyrosine (Tyr), Xaa2 is phenylalanine (Phe) or leucine (Leu), Xaa3 is lysine (Lys) or glutamic acid (Glu), Xaa4 is aspartic acid (Asp) or valine (Vai), Xaa5 is alanine (Ala) or arginine (Arg), Xaa6 is lysine (Lys) or threonine (Thr), Xaa7 is alanine (Ala) or serine (Ser), Xaa8 is serine (Ser) or threonine (Thr), Xaa9 is tyrosine (Tyr) or phenylalanine (Phe), and XaalO is asparagine (Asn) or serine (Ser), Xaal 1 is tyrosine (Tyr) or histidine (His), Xaal2 is alanine (Ala) or valine (Vai), and Xaal 3 is glutamic acid (Glu) or aspartic acid (Asp).In some embodiments, the Ig heavy chain polypeptide comprises SEQ ID NO: 26, provided that it retains the same CDRs (CDR1, CDR2, and CDR3) of any of SEQ ID NOs: 1-15, 207, 208, 217, or 218.

[0038] According to this aspect of the disclosure, the immunoglobulin light chain polypeptide of the BTLA-binding agent can comprise the amino acid sequence of any one of SEQ ID NOs: 16-25, 209, 210, 219, or 220, or at least the CDRs thereof; or an amino acid sequence with at least 80% sequence identity (e.g., at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity) to any one of SEQ ID NOs:16-25, 209, 210, 219, or 220. As with the Ig heavy chain, the CDRs can be as determined using any known numbering scheme, such as such as Kabat, Chothia, Martin (Enhanced Chothia), IGMT, or AHo. In some embodiments, CDR1, CDR2, and CDR3 comprise residues 24-34 (CDRL1), 50-56 (CDRL2), and 89-97 (CDRL3) of SEQ ID NOs: 16-25, 209, 210, 219, or 220.

[0039] In some embodiments, the Ig light chain comprises the following CDRs:(a) a CDRL1 comprising Lys Ala Ser Gin Asn Vai Phe Thr Asn Vai Ala (SEQ ID NO: 36);(b) a CDRL2 comprising Ser Ala Ser Tyr Arg Xaa Ser (SEQ ID NO: 39), wherein Xaa is tyrosine (Tyr) or serine (Ser) (e.g., SEQ ID NO: 37, 40, 215, or 225); and(c) a CDRL3 comprising Gin Gin Tyr Xaal Xaa2 Tyr Pro Tyr Thr (SEQ ID NO: 41), wherein Xaal is serine (Ser) or asparagine (Asn), and Xaa2 is threonine (Thr) or serine (Ser) (e.g., SEQ ID NO: 38, 41, 42, 216, or 226).

[0040] In other embodiments, the immunoglobulin light chain polypeptide comprises the amino acid sequence Asp He Vai Met Thr Gin Ser Pro Asp Ser Leu Ala Vai Ser Leu Gly Glu Arg Ala Thr He Asn Cys Lys Ala Ser Gin Asn Vai Phe Thr Asn Vai Ala Trp Tyr Gin Gin Lys Pro Gly Gin Xaal Pro Lys Xaa2 Leu He Tyr Ser Ala Ser Tyr Arg Xaa3 Ser Gly Vai Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr He Ser Ser Leu Gin Ala Glu Asp Vai Ala Vai Tyr Xaa4 Cys Gin Gin Tyr Xaa5 Xaa6 Tyr Pro Tyr Thr Phe Gly Gin Gly Thr Lys Leu Glu He Lys Arg (SEQ ID NO: 35), or at least the CDR regions thereof, whereinXaal is serine (Ser) or proline (Pro), Xaa2 is proline (Pro) or leucine (Leu), Xaa3 is tyrosine (Tyr) or serine (Ser), Xaa4 is tyrosine (Tyr) or phenylalanine (Phe), Xaa5 is serine (Ser) or asparagine (Asn), and Xaa6 is threonine (Thr) or serine (Ser).In some embodiments, the Ig light chain polypeptide comprises SEQ ID NO: 35, provided that it retains the same CDRs (CDR1, CDR2, and CDR3) of any one of SEQ ID NOs: 16-25, 209, 210, 219, or 220.

[0041] In another aspect of the disclosure, the BTLA-binding agent comprises an immunoglobulin heavy chain polypeptide comprising any one of SEQ ID NOs: 43-156, or at least the CDRs thereof; or an amino acid sequence with at least 80% , 85%, or 90% sequence identity (e.g., at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity) to any one of SEQ ID NOs: 43-156. The CDRs can be as determinedusing any known numbering scheme, such as such as Kabat, Chothia, Martin (Enhanced Chothia), IGMT, or AHo. In some embodiments, CDR1, CDR2, and CDR3 comprise residues 31-35 (CDRH1), 50-66 (CDRH2), and 99-113 (CDRH3) of SEQ ID NOs: 43-156, with the exception that in SEQ ID NO: 66, CDRH1 can be residues 50-67 and CDRH3 can be residues 100-114; and in SEQ ID NOs: 141, 150, 152, 153, 155, and 156 CDRH3 can be residues 100- 114.

[0042] In some embodiments, the immunoglobulin heavy chain polypeptide comprises the following CDRs:(a) a CDRH1 comprising X1SX2MN (SEQ ID NO: 195), wherein X1is N or T, and X2is W, F, H, G, P, R, K, D, S, L, V, N, or Y;(b) a CDRH2 comprising RIYPX1GX2X3DTNYX4GKFK (SEQ ID NO: 196), wherein: X1is absent or A;X2is D, Y, Q, G, L, F, H, S, P, R, or T;X3is G, Y, A, F, S, D, V, T, E, K, or R; andX4is N, V, Q, R, A, F, Y, S, G, P, or T; and(c) a CDRH3 comprising X^GTFX^GNYX^YFDV (SEQ ID NO: 197), wherein: X1is K or R;X2is N or D;X3is D, S, F, Y, F, V, S, G, T, R, I, L, or E;X4is R or H; andX5is W, R, F, L, N, Y, P, I, V, A, S, G, R, or K.

[0043] In some embodiments, the Ig heavy chain comprises a CDRH1 comprising SEQ ID NO: 201; a CDRH2 comprising SEQ ID NO: 202; and a CDRH3 comprising SEQ ID NO: 203.

[0044] In some embodiments, the BTLA-binding agent comprises an immunoglobulin heavy chain polypeptide comprising the sequence: QVQLVQSGAEVKKPGSSVKVSCKASGYX1FSX2SX3MNWVRQAPGQGLEWMGRIYPX4GX5X6DTNYX7GKFKGRVTITADKX8TX9TAYMELX10SLRSEX11TAVX12YX13CAX14SGTF X15X16GNYX17X18YFDVWGKGTTVTVSSA (SEQ ID NO: 193), or at least the CDR regions thereof, whereinX1is A or V;X2is N or T;X3is W, F, H, G, P, R, K, D, S, L, V, N, or Y;X4is absent or A;X5is D, Y, Q, G, L, F, H, S, P, R, or T;X6is G, Y, A, F, S, D, V, T, E, K, or R;X7is N, V, Q, R, A, F, Y, S, G, P, or T;X8is S or F;X9is S, T, or N;X10is S or R;X11is D or V;X12is absent or Y;X13is Y or F;X14is K or R;Xl 5is N or D;X16is D, S, F, Y, F, V, S, G, T, R, I, L, or E;X17is R or H; andX18is W, R, F, L, N, Y, P, I, V, A, S, G, R, or K.In some embodiments, the Ig heavy chain polypeptide comprises SEQ ID NO: 193, provided that it retains the same CDRs (CDR1, CDR2, and CDR3) of any of SEQ ID NOs: 43-156.

[0045] According to this aspect of the disclosure, the binding agent further comprises an Ig light chain comprising any of SEQ ID NOs: 157-192, or at least the CDRs thereof; or an amino acid sequence with at least 80% , 85%, or 90% sequence identity (e.g., at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity) to any one of SEQ ID NOs: 157-192. The CDRs can be as determined using any known numbering scheme, such as such as Kabat, Chothia, Martin (Enhanced Chothia), IGMT, or AHo. In some embodiments, CDR1, CDR2, and CDR3 comprise residues 24-34 (CDRL1), 50-56 (CDRL2), and 89-97 (CDRL3) of SEQ ID NOs: 157-192.

[0046] In some embodiments, the BTLA-binding agent can comprise an immunoglobulin light chain polypeptide comprising:(a) a CDRL1 comprising RX1SENIYX2X3LA (SEQ ID NO: 198), whereinX1is A or V;X2is S or N; andX3is H, N, or Y;(b) a CDRL2 comprising X’AX2NLAX3(SEQ ID NO: 199), whereinX1is A or N;X2is T or K; andX3is N, L, Q, G, F, V, K, S, R, T, H, or P; and(c) a CDRL3 comprising QX1FX2GPPLT (SEQ ID NO: 200), whereinX1is L or H; andX2is W, F, Y, P, N, V, K, M, L, G, or S.

[0047] In some embodiments, the Ig light comprises a CDRL1 comprising SEQ ID NO: 204; a CDRL2 comprising SEQ ID NO: 205; and a CDRL3 comprising SEQ ID NO: 206.

[0048] In some embodiments, the immunoglobulin light chain polypeptide comprises the sequence:X1IQX2TQSPSSLSASVGDRVTITCRX3SENIYX4X5LAWYQQKX6GKAPKLLIYX7AX8NLAX9GVPSRFSGSGSGTDX10TLTISSLQPEDFATYYCQXnFX12GPPLTFGGGTKVEIKR (SEQID NO: 194), or at least the CDRs thereof, whereinX1is A or D;X2is L or M;X3is A or V;X4is S or N;X5is H, N, or Y;X6is P or Q;X7is A or N;X8is T or K;X9is N, L, Q, G, F, V, K, S, R, T, H, or P;X10is F or Y;X11is L or H;X12is W, F, Y, P, N, V, K, M, L, G, S.In some embodiments, the Ig light chain polypeptide comprises SEQ ID NO: 194, provided that it retains the same CDRs (CDR1, CDR2, and CDR3) of any one of SEQ ID NOs: 157-192.

[0049] According to one embodiment, the BTLA-binding agent comprises an immunoglobulin heavy chain variable region of SEQ ID NO: 144 or an amino acid sequence with at least 80% , 85% , or 90% sequence identity (e.g., at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity) thereto; or an immunoglobulin heavy chain variable region comprising at least the CDRs of SEQ ID NO: 144, wherein the CDR regions are as provided above (e.g., CDR1 - SEQ ID NO: 201, CDR2 - SEQ ID NO: 202, and CDR3 - SEQ ID NO: 203) or as determined in accordance with any of the various known immunoglobulin numbering schemes (e.g., Kabat, Chothia, Martin (Enhanced Chothia), IGMT, or AHo); and an immunoglobulin light chain variable region of SEQ ID NO: 174 or an amino acid sequence with at least 80% , 85% , or 90% sequence identity (e.g., at least 80%, at least81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity) thereto, or an immunoglobulin light chain variable region comprising at least the CDRs of SEQ ID NO: 174; wherein the CDR regions are as provided above (e.g., CDR1 - SEQ ID NO: 204, CDR2 - SEQ ID NO: 205, and CDR3 - SEQ ID NO: 206) or as determined in accordance with any of the various known immunoglobulin numbering schemes (e.g., Kabat, Chothia, Martin (Enhanced Chothia), IGMT, or AHo). In some embodiments, the antibody comprises a heavy chain variable region of SEQ ID NO: 144 and light chain variable region of SEQ ID NO: 174, or at least the CDRs thereof as determined by Kabat. In some embodiments, the antibody comprises a heavy chain variable region of SEQ ID NO: 144 and light chain variable region of SEQ ID NO: 174, or at least the CDRs thereof as determined by Chothia. In some embodiments, the antibody comprises a heavy chain variable region of SEQ ID NO: 144 and light chain variable region ofSEQ ID NO: 174, or at least the CDRs thereof as determined by Martin. In some embodiments, the antibody comprises a heavy chain variable region of SEQ ID NO: 144 and light chain variable region of SEQ ID NO: 174, or at least the CDRs thereof as determined by IGMT. In some embodiments, the antibody comprises a heavy chain variable region of SEQ ID NO: 144 and light chain variable region of SEQ ID NO: 174, or at least the CDRs thereof as determined by A Ho.

[0050] Also provided is a BTLA-binding agent that binds to the same epitope as a BTLA- binding agent comprising the immunoglobulin heavy and light chain polypeptides set forth herein. In some embodiments, the BTLA-binding agent binds to the same epitope as a BTLA binding agent comprising a heavy chain variable region of SEQ ID NO: 144 and a light chain variable region of SEQ ID NO: 174. In some embodiments, the BTLA binding agent binds to the same epitope as a BTLA binding agent comprising a heavy chain variable region of SEQ ID NO: 5 and a light chain variable region comprising SEQ ID NO: 17; a BTLA binding agent comprising a heavy chain variable region of SEQ ID NO: 207 and a light chain variable region comprising SEQ ID NO: 209; or a BTLA binding agent comprising a heavy chain variable region of SEQ ID NO: 217 and a light chain variable region comprising SEQ ID NO: 219. A BTLA-binding agent is considered to bind to the same epitope if it competes for binding to BTLA with a BTLA-binding agent comprising the immunoglobulin heavy and light chain polypeptides described herein. In some embodiments, provided herein is a BTLA binding agent that binds to amino acid residues 52-65 and / or 100-106 of human BTLA (e.g., SEQ ID NOs: 227 and / or 228) (reference sequence UniProt ID Q7Z6A9 or corresponding sequence positions of naturally occurring variant human BTLA). In some embodiments, provided herein is a BTLA binding agent that binds to amino acid residues 46065, 82-91, or 100-106 of human BTLA (e.g., SEQ ID NOs: 229, 230, and / or 231) (reference sequence UniProt ID Q7Z6A9 or corresponding sequence positions of naturally occurring variant human BTLA).

[0051] Sequence “identity” as used in reference to nucleic acid or amino acid sequences can be determined by comparing a nucleic acid or amino acid sequence of interest to a reference nucleic acid or amino acid sequence. The percent identity is the percentage of nucleotides or amino acid residues that are the same (i.e., that are identical) as between the sequence of interest and the reference sequence when optimally aligned. A number of mathematical algorithms forobtaining the optimal alignment and calculating identity between two or more sequences are known and publically available. Examples of such programs include CLUSTAL-W, T-Coffee, and ALIGN (for alignment of nucleic acid and amino acid sequences), BLAST programs (e.g., BLAST 2.1, BL2SEQ, and later versions thereof operated by the National Center for Biotechnology Information, Bethesda, MD) and FASTA programs (e.g., FASTA3x, FASTM, and S SEARCH) (for sequence alignment and sequence similarity searches). Sequence alignment algorithms also are disclosed in, for example, Altschul et al., J. Molecular Biol. , 215(3)'. 403-410 (1990), Beigert et al., Proc. Natl. Acad. Sci. USA, 106(\G '. 3770-3775 (2009), Durbin et al., eds., Biological Sequence Analysis: Probalistic Models of Proteins and Nucleic Acids, Cambridge University Press, Cambridge, UK (2009), Soding, Bioinformatics, 21(1)'. 951-960 (2005), Altschul et al., Nucleic Acids Res., 25( Ty. 3389-3402 (1997), and Gusfield, Algorithms on Strings, Trees and Sequences, Cambridge University Press, Cambridge UK (1997)).

[0052] With respect to sequences having less than 100% identity to the heavy and light chain sequences specifically set forth above, one or more amino acids of the aforementioned immunoglobulin heavy chain polypeptides and / or light chain polypeptides can be replaced or substituted with a different amino acid, and / or one of more amino acids can be deleted from or inserted into the disclosed amino acid sequences, provided the activity of the polypeptide (e.g., the ability to bind BTLA when present as part of an BTLA-binding agent) is substantially retained. The “biological activity” of a BTLA-binding agent refers to, for example, binding affinity for a particular BTLA epitope (without inhibiting BTLA-binding to its receptor and / or without inhibiting BTLA activity in vivo (e.g., ICso)), pharmacokinetics, and cross-reactivity (e.g., with non-human homologs or orthologues of the BTLA protein, or with other proteins or tissues). In some embodiments, the biological activity of the BTLA-binding agent includes the ability of the agent to enhance BTLA-binding to its receptor(s) and / or otherwise increase BTLA activity in vivo. Other biological properties or characteristics of an antigen-binding agent recognized in the art include, for example, avidity, selectivity, solubility, folding, immunotoxicity, expression, and formulation. The aforementioned properties or characteristics can be observed, measured, and / or assessed using standard techniques including, but not limited to, ELISA, competitive ELISA, surface plasmon resonance analysis (BIACORE™), or solution phase competition (KINEXA™), in vitro or in vivo neutralization assays, receptor-ligand bindingassays, cytokine or growth factor production and / or secretion assays, and signal transduction and immunohistochemistry assays.

[0053] An amino acid replacement or substitution can be conservative, semi-conservative, or non-conservative. The phrase “conservative amino acid substitution” or “conservative mutation” refers to the replacement of one amino acid by another amino acid with a common property. A functional way to define common properties between individual amino acids is to analyze the normalized frequencies of amino acid changes between corresponding proteins of homologous organisms (Schulz and Schirmer, Principles of Protein Structure, Springer-Verlag, New York (1979)). According to such analyses, groups of amino acids may be defined where amino acids within a group exchange preferentially with each other, and therefore resemble each other most in their impact on the overall protein structure (Schulz and Schirmer, supra).

[0054] Amino acids are broadly grouped as “aromatic” or “aliphatic.” An aromatic amino acid includes an aromatic ring. Examples of “aromatic” amino acids include histidine (H or His), phenylalanine (F or Phe), tyrosine (Y or Tyr), and tryptophan (W or Trp). Non-aromatic amino acids are broadly grouped as “aliphatic.” Examples of “aliphatic” amino acids include glycine (G or Gly), alanine (A or Ala), valine (V or Vai), leucine (L or Leu), isoleucine (I or He), methionine (M or Met), serine (S or Ser), threonine (T or Thr), cysteine (C or Cys), proline (P or Pro), glutamic acid (E or Glu), aspartic acid (A or Asp), asparagine (N or Asn), glutamine (Q or Gin), lysine (K or Lys), and arginine (R or Arg).

[0055] Aliphatic amino acids may be sub-divided into four sub-groups. The “large aliphatic non-polar sub-group” consists of valine, leucine, and isoleucine. The “aliphatic slightly-polar sub-group” consists of methionine, serine, threonine, and cysteine. The “aliphatic polar / charged sub-group” consists of glutamic acid, aspartic acid, asparagine, glutamine, lysine, and arginine. The “small-residue sub-group” consists of glycine and alanine. The group of charged / polar amino acids may be sub-divided into three sub-groups: the “positively-charged sub-group” consisting of lysine and arginine, the “negatively-charged sub-group” consisting of glutamic acid and aspartic acid, and the “polar sub-group” consisting of asparagine and glutamine.

[0056] Aromatic amino acids may be sub-divided into two sub-groups: the “nitrogen ring sub-group” consisting of histidine and tryptophan and the “phenyl sub-group” consisting of phenylalanine and tyrosine.

[0057] Examples of conservative amino acid substitutions include substitutions of amino acids within the sub-groups described above, for example, lysine for arginine and vice versa such that a positive charge may be maintained, glutamic acid for aspartic acid and vice versa such that a negative charge may be maintained, serine for threonine such that a free -OH can be maintained, and glutamine for asparagine such that a free -NH2 can be maintained. “Semiconservative mutations” include amino acid substitutions of amino acids within the same groups listed above, but not within the same sub-group. For example, the substitution of aspartic acid for asparagine, or asparagine for lysine, involves amino acids within the same group, but different sub-groups. “Non-conservative mutations” involve amino acid substitutions between different groups, for example, lysine for tryptophan, or phenylalanine for serine, etc.

[0058] The foregoing mutations (e.g., substitutions) may be made in any region of the Ig chain. In some embodiments, amino acid(s) are substituted in a CDR (e.g., CDR1, CDR2, or CDR3) of the immunoglobulin heavy chain polypeptide and / or light chain polypeptide; in other embodiments, the amino acid(s) are substituted in the framework regions and not the CDRs; in still other embodiments, the amino acids substituted in both the framework regions and CDRs. In some embodiments, the foregoing mutations are made in regions other than in the CDRs. In other words, the heavy chain variable region and light chain variable region can have the stated sequence identity to the sequences provided herein, but retain the CDRs of the specifically provided sequence.

[0059] In addition, one or more amino acids can be inserted into the aforementioned immunoglobulin heavy chain polypeptides and / or light chain polypeptides, provided it does not abrogate the function of the polypeptide in the context of the BTLA-binding agent (e.g., does not prevent a binding agent comprising the polypeptide from binding to BTLA without inhibiting BTLA from binding to its receptor). Any number of any suitable amino acids can be inserted into the amino acid sequence of the immunoglobulin heavy chain polypeptide and / or light chain polypeptide. In some embodiments, at least one amino acid (e.g., 2 or more, 5 or more, or 10 or more amino acids), but not more than 20 amino acids (e.g., 18 or less, 15 or less, or 12 or less amino acids), can be inserted into the amino acid sequence of the immunoglobulin heavy chain polypeptide and / or light chain polypeptide. In other embodiments, 1-10 amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids) are inserted into the amino acid sequence of theimmunoglobulin heavy chain polypeptide and / or light chain polypeptide. In this respect, the amino acid(s) can be inserted into any one of the aforementioned immunoglobulin heavy chain polypeptides and / or light chain polypeptides in any suitable location. In some embodiments, the amino acid(s) are inserted into a CDR (e.g., CDR1, CDR2, or CDR3) of the immunoglobulin heavy chain polypeptide and / or light chain polypeptide; in other embodiments, the amino acid(s) are inserted into the framework regions and not the CDRs; in still other embodiments, the amino acids are inserted in both the framework regions and CDRs.

[0060] The inventive isolated immunoglobulin heavy chain polypeptide and light chain polypeptides are not limited to polypeptides comprising the specific amino acid sequences described herein, and also includes any heavy chain polypeptide or light chain polypeptide that competes with the inventive immunoglobulin heavy chain polypeptide or light chain polypeptide for binding to BTLA when included in a BTLA-binding agent. In this respect, for example, the immunoglobulin heavy chain polypeptide or light chain polypeptide can be any heavy chain polypeptide or light chain polypeptide that binds to the same epitope of BTLA recognized by the heavy and light chain polypeptides described herein when included in a BTLA-binding agent. Antibody competition can be assayed using routine peptide competition assays, which utilize ELISA, Western blot, or immunohistochemistry methods (see, e.g., U.S. Patents 4,828,981 and 8,568,992; and Braitbard et al., Proteome Set., 4 12 (2006)).

[0061] The BTLA-binding agent is a proteinaceous molecule comprising the immunoglobulin heavy chain variable region and light chain variable region set forth herein that specifically binds to the BTLA protein (e.g., an antibody or an antigen-binding fragment thereof). In some embodiments, the BTLA-binding agent binds BTLA without abrogating or, in some embodiments, without inhibiting BTLA-binding to its receptor. In some embodiments, the BTLA-binding agent enhances binding of BTLA to HVEM so as to increase BTLA-mediated signaling. The term “inhibit” as used herein with respect to binding of BTLA to its receptor or BTLA-mediated signaling refers to the ability to substantially antagonize, prohibit, prevent, restrain, slow, disrupt, alter, eliminate, or stop (in whole or in part), the binding of BTLA to its receptor or BTLA-HVEM mediated signaling in the presence of the binding agent as compared to such binding or signaling in the absence of the binding agent. The term “increase” or “enhance” as used in reference to BTLA-binding to its receptor or BTLA-mediated signalingmeans to increase or enhance such binding or signaling in any way and to any degree in the presence of the binding agent as compared to such binding or signaling in the absence of the binding agent. In some embodiments, BTLA-binding to its receptor or BTLA-mediated signaling is increased sufficiently to reduce or alleviate any symptom of a disease or condition associated with deficient BTLA activity, or which benefits from enhanced BTLA activity, or to reverse the progression or severity of such a disease or condition. In some embodiments, the BTLA-binding agent does not inhibit BTLA-receptor binding by more than 25% (e.g., does not inhibit BTLA-receptor binding by more than 10% or more than 5%). In some embodiments, the BTLA-binding agent increases BTLA-receptor binding by at least about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 100%, or a range defined by any two of the foregoing values, as compared to the activity of BTLA in the absence of the BTLA-binding agent.

[0062] The BTLA-binding agent can be part of a multispecific (e.g., bispecific or “dual reactive”) construct (e.g., a multispecific antibody, such as a bispecific or dual reactive antibody) that binds BTLA and another antigen. Such a construct can comprise immunoglobulin heavy and light chain polypeptides that bind BTLA as described herein in combination with immunoglobulin heavy chains and light chains from an immunoglobulin that binds an antigen other than BTLA. Such a bispecific BTLA-binding agent can bind, for example, BTLA and another negative regulator of the immune system, such as cytotoxic T lymphocyte antigen-4 (CTLA-4), T Cell Immunoglobulin and Mucin Domain-3 (TIM-3), programmed death 1 (PD-1) and / or the Lymphocyte Activation Gene 3 protein (LAG-3). Immunoglobulins that bind such other target antigens are known in the art.

[0063] Antibody conjugates also are provided herein. For example, the BTLA-binding agent can be a conjugate of (1) an anti-BTLA antibody or fragment thereof, and (2) a secondary protein or non-protein moiety. By way of further illustration, the BTLA-binding agent can comprise an anti-BTLA antibody or fragment thereof conjugated to another peptide, a fluorescent molecule, or a chemotherapeutic agent.

[0064] In some embodiments, the BTLA-binding agent can be a “whole” immunoglobulin or an antigen-binding immunoglobulin “fragment.” A “whole” immunoglobulin typically consists of four polypeptides: two heavy (H) chain polypeptides and two light (L) chain polypeptides.Each of the heavy chains contains one N-terminal variable (VH) region and three C-terminal constant (CHI, CH2, and CH3) regions, and each light chain contains one N-terminal variable (VL) region and one C-terminal constant (CL) region. The light chains of antibodies can be assigned to one of two distinct types, either kappa (K) or lambda ( ), based upon the amino acid sequences of their constant domains. In a typical immunoglobulin, each light chain is linked to a heavy chain by disulfide bonds, and the two heavy chains are linked to each other by disulfide bonds. In this configuration, the light chain variable region is generally aligned with the variable region of the heavy chain, and the light chain constant region is generally aligned with the first constant region of the heavy chain. The remaining constant regions of the heavy chains are generally aligned with each other.

[0065] The variable regions or hypervariable regions of each pair of light and heavy chains form the antigen binding site of an antibody. The VH and VL regions have the same general structure, with each region comprising four framework (FW or FR) regions. The term “framework region,” as used herein, refers to the relatively conserved amino acid sequences within the variable region, which are located between the hypervariable or complementary determining regions (CDRs). There are four framework regions in each variable domain, which are designated FR1, FR2, FR3, and FR4. The framework regions form the 0 sheets that provide the structural framework of the variable region (see, e g., C.A. Janeway et al. (eds.), Immunobiology, 5th Ed., Garland Publishing, New York, NY (2001)). The framework regions are connected by three complementarity determining regions (CDRs). The three CDRs, known as CDR1, CDR2, and CDR3, form the “hypervariable region” of an antibody, which is generally considered to be responsible for antigen binding.

[0066] The term “antibody fragment” and like terms (e.g., “fragment of an antibody,” “antibody fragment,” “functional fragment of an antibody”) are used interchangeably herein to mean one or more fragments or portions of an antibody that retain the ability to specifically bind to an antigen (see, generally, Holliger et al., Nat. Biotech., 23(9): 1126-1129 (2005)). Antibody “fragments,” as used herein and routinely in the art, include not only fragments or pieces of a whole antibody in the literal sense, but also other known engineered antibody-like constructs, which might include linkers or other elements that do not occur in a natural antibody in addition to a fragment of an antibody. The antibody fragment can comprise, for example, one or more (orall) of the CDRs, the variable regions (or portions thereof), the constant regions (or portions thereof), or some combination thereof. Examples of antibody fragments include, but are not limited to, (i) a Fab fragment, which is a monovalent fragment consisting of the VL, VH, CL, and CHi domains, (ii) a F(ab’)2 fragment, which is a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region, (iii) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (iv) a Fab’ fragment, which results from breaking the disulfide bridge of an F(ab’)2 fragment using mild reducing conditions, (v) a disulfide-stabilized Fv fragment (dsFv), and (vi) a domain antibody (dAb), which is an antibody single variable region domain (VH or VL) polypeptide that specifically binds antigen. The BTLA-binding agent also can be a single chain antibody fragment. Examples of single chain antibody fragments include, but are not limited to, (i) a single chain Fv (scFv), which is a monovalent molecule consisting of the two domains of the Fv fragment (i.e., VL and VH) joined by a synthetic linker which enables the two domains to be synthesized as a single polypeptide chain (see, e.g., Bird et al., Science, 242'. 423-426 (1988); Huston et al., Proc. Natl. Acad. Sci. USA, 85: 5879-5883 (1988); and Osbourn et al., Nat. Biotechnol, 16. 778 (1998)) and (ii) a diabody, which is a dimer of polypeptide chains, wherein each polypeptide chain comprises a VH connected to a VL by a peptide linker that is too short to allow pairing between the VH and VL on the same polypeptide chain, thereby driving the pairing between the complementary domains on different VH -VL polypeptide chains to generate a dimeric molecule having two functional antigen binding sites. Antibody fragments are known in the art and are described in more detail in, e.g., U.S. Patent Application Publication 2009 / 0093024 Al.

[0067] In some embodiments, the BTLA-binding agent comprises a heavy chain constant region, such as a fragment crystallizable (Fc) region or portion thereof. The Fc region can be of any Ig class / subclass (IgA (IgAl, IgA2), IgD, IgE, IgG (IgGl, IgG2, IgG3 and IgG4), IgM, including variants thereof. In some embodiments, the BTLA-binding agent is a “whole” or “complete” Ig (i.e., an antibody). In some embodiments, the BTLA binding agent comprises an IgG Fc region, such as IgGl or IgG4. For instance, the BETA binding agent can be an IgGl or IgG4 antibody. In some embodiments, the BTLA binding agent comprises a variable heavy chain region and variable light chain region comprising SEQ ID NOs: 144 and 174, respectively, or at least the CDRs thereof (as provided herein or as determined according to Kabat, Chothia,Martin (Enhanced Chothia), IGMT, or AHo numbering), or sequences comprising 90% identity thereto, wherein the BTLA binding agent is an IgGl antibody. In some embodiments, the BTLA binding agent comprises a variable heavy chain region and variable light chain region comprising SEQ ID NOs: 144 and 174, respectively, or at least the CDRs thereof (as provided herein or as determined according to Kabat, Chothia, Martin (Enhanced Chothia), IGMT, or AHo numbering), or sequences comprising 90% identity thereto, wherein the BTLA binding agent is an IgG4 antibody.

[0068] The BTLA-binding agent can be, or can be obtained from, a human antibody, a nonhuman antibody, or a chimeric antibody. By “chimeric” is meant an antibody or fragment thereof comprising both human and non-human regions. Preferably, the BTLA-binding agent is a humanized antibody. A “humanized” antibody is a monoclonal antibody comprising a human antibody scaffold and at least one CDR obtained or derived from a non-human antibody. Non- human antibodies include antibodies isolated from any non-human animal, such as, for example, a rodent (e.g., a mouse or rat). A humanized antibody can comprise, one, two, or three CDRs obtained or derived from a non-human antibody. In one embodiment of the invention, CDRH3 of the inventive BTLA-binding agent is obtained or derived from a mouse monoclonal antibody, while the remaining variable regions and constant region of the inventive BTLA-binding agent are obtained or derived from a human monoclonal antibody.

[0069] A human antibody, a non-human antibody, a chimeric antibody, or a humanized antibody can be obtained by any means, including via in vitro sources (e.g., a hybridoma or a cell line producing an antibody recombinantly) and in vivo sources (e.g., rodents). Methods for generating antibodies are known in the art and are described in, for example, Kohler and Milstein, Eur. J. Immunol., 5 511-519 (1976); Harlow and Lane (eds ), Antibodies: A Laboratory Manual, CSH Press (1988); and Janeway et al. (eds.), Immunobiology, 5th Ed., Garland Publishing, New York, NY (2001)). In certain embodiments, a human antibody or a chimeric antibody can be generated using a transgenic animal (e.g., a mouse) wherein one or more endogenous immunoglobulin genes are replaced with one or more human immunoglobulin genes. Examples of transgenic mice wherein endogenous antibody genes are effectively replaced with human antibody genes include, but are not limited to, the Medarex HUMAB- MOUSE™, the Kirin TC MOUSE™, and the Kyowa Kirin KM-MOUSE™ (see, e.g., Lonberg,Nat. Biotechnol., 23(9): 1117-25 (2005), and Lonberg, Handb. Exp. Pharmacol., 181: 69-97 (2008)). A humanized antibody can be generated using any suitable method known in the art (see, e.g., An, Z. (ed.), Therapeutic Monoclonal Antibodies: From Bench to Clinic, John Wiley & Sons, Inc., Hoboken, New Jersey (2009)), including, e.g., grafting of non-human CDRs onto a human antibody scaffold (see, e.g., Kashmiri et al., Methods, 56(1): 25-34 (2005); and Hou et al., J. Biochem., 144(1): 115-120 (2008)). In one embodiment, a humanized antibody can be produced using the methods described in, e.g., U.S. Patent Application Publication 2011 / 0287485 Al.

[0070] The BTLA-binding agent is not limited by any particular affinity to its epitope. The term “affinity” refers to the equilibrium constant for the reversible binding of two agents and is expressed as the dissociation constant (KD). However, in some embodiments, the BTLA can have an affinity for BTLA of from about 1 picomolar (pM) to about 100 micromolar (pM) (e.g., from about 1 picomolar (pM) to about 1 nanomolar (nM), from about 1 nM to about 1 micromolar (pM), or from about 1 pM to about 100 pM). In one embodiment, the BTLA- binding agent can bind to an BTLA protein with a KD less than or equal to 1 nanomolar (e.g., 0.9 nM, 0.8 nM, 0.7 nM, 0.6 nM, 0.5 nM, 0.4 nM, 0.3 nM, 0.2 nM, 0.1 nM, 0.05 nM, 0.025 nM, 0.01 nM, 0.001 nM, or a range defined by any two of the foregoing values). In another embodiment, the BTLA-binding agent can bind to BTLA with a KD less than or equal to 200 pM (e.g., 190 pM, 175 pM, 150 pM, 125 pM, 110 pM, 100 pM, 90 pM, 80 pM, 75 pM, 60 pM, 50 pM, 40 pM, 30 pM, 25 pM, 20 pM, 15 pM, 10 pM, 5 pM, 1 pM, or a range defined by any two of the foregoing values). Immunoglobulin affinity for an antigen or epitope of interest can be measured using any art-recognized assay. Such methods include, for example, fluorescence activated cell sorting (FACS), separable beads (e.g., magnetic beads), surface plasmon resonance (SPR), solution phase competition (KINEXA™), antigen panning, competitive binding assays, and / or ELISA (see, e.g., Janeway et al. (eds.), Immunobiology, 5th ed., Garland Publishing, New York, NY, 2001). In some embodiments, the BTLA binding agent has an affinity to BTLA as described above (e.g., 1 nM or less or 200 pM or less) when measured using surface plasmon resonance (SPR). In some embodiments, the BTLA binding agent has an affinity to BTLA as described above (e.g., 1 nM or less or 200 pM or less) when measured using surface plasmon resonance (SPR).

[0071] The BTLA-binding agent can be part of a composition suitable for administration to a mammal. Preferably, the composition is a pharmaceutically acceptable (e.g., physiologically acceptable) composition, which comprises a carrier, preferably a pharmaceutically acceptable (e g., physiologically acceptable) carrier, and the inventive amino acid sequences, antigenbinding agent, or vector. Any suitable carrier can be used within the context of the invention, and such carriers are well known in the art. The choice of carrier will be determined, in part, by the particular site to which the composition may be administered and the particular method used to administer the composition. The composition also can comprise any other excipient used in the formulation of therapeutic molecules (e.g., proteins or antibodies), particularly parenteral formulations, including, for instance, buffers, tonicity modifiers, stabilizers, surfactants and the like. The composition optionally can be sterile. The composition can be frozen or lyophilized for storage and reconstituted in a suitable sterile carrier prior to use. The compositions can be generated in accordance with conventional techniques described in, e.g., Remington: The Science and Practice of Pharmacy, 21st Edition, Lippincott Williams & Wilkins, Philadelphia, PA (2001).

[0072] A typical dose can be, for example, in the range of 1 pg / kg to 20 mg / kg of animal or human body weight; however, doses below or above this exemplary range are within the scope of the invention. The daily parenteral dose can be about 0.00001 pg / kg to about 20 mg / kg of total body weight (e.g., about 0.001 pg / kg, about 0.1 pg / kg , about 1 pg / kg, about 5 pg / kg, about 10 pg / kg, about 100 pg / kg, about 500 pg / kg, about 1 mg / kg, about 5 mg / kg, about 10 mg / kg, or a range defined by any two of the foregoing values), preferably from about 0.1 pg / kg to about 10 mg / kg of total body weight (e.g., about 0.5 pg / kg, about 1 pg / kg, about 50 pg / kg, about 150 pg / kg, about 300 pg / kg, about 750 pg / kg, about 1.5 mg / kg, about 5 mg / kg, or a range defined by any two of the foregoing values), more preferably from about 1 pg / kg to 5 mg / kg of total body weight (e.g., about 3 pg / kg, about 15 pg / kg, about 75 pg / kg, about 300 pg / kg, about 900 pg / kg, about 2 mg / kg, about 4 mg / kg, or a range defined by any two of the foregoing values), and even more preferably from about 0.5 to 15 mg / kg body weight per day (e.g., about 1 mg / kg, about 2.5 mg / kg, about 3 mg / kg, about 6 mg / kg, about 9 mg / kg, about 11 mg / kg, about 13 mg / kg, or a range defined by any two of the foregoing values). Therapeutic or prophylactic efficacy can be monitored by periodic assessment of treated patients. For repeatedadministrations over several days or longer, depending on the condition, the treatment can be repeated until a desired suppression of disease symptoms occurs, or alternatively, the treatment can be continued for the lifetime of the patient. However, other dosage regimens may be useful and are within the scope of the invention. The desired dosage can be delivered by a single bolus administration of the composition, by multiple bolus administrations of the composition, or by continuous infusion administration of the composition.

[0073] Administration may be effected using any standard administration techniques, including oral, intravenous, intraperitoneal, subcutaneous, pulmonary, transdermal, intramuscular, intranasal, buccal, sublingual, or suppository administration. The composition preferably is suitable for parenteral administration. The term “parenteral,” as used herein, includes intravenous, intramuscular, subcutaneous, rectal, vaginal, and intraperitoneal administration. More preferably, the composition is administered to a mammal using peripheral systemic delivery by intravenous, intraperitoneal, or subcutaneous injection.

[0074] Once administered to a mammal (e.g., a human), the biological activity of the BTLA- binding agent can be measured by any suitable method known in the art. The biological activity may be correlated to the stability of the BTLA-binding agent in the body. In one embodiment of the invention, the BTLA-binding agent (e.g., an antibody) has an in vivo half-life between about 30 minutes and 45 days (e.g., about 30 minutes, about 45 minutes, about 1 hour, about 2 hours, about 4 hours, about 6 hours, about 10 hours, about 12 hours, about 1 day, about 5 days, about 10 days, about 15 days, about 25 days, about 35 days, about 40 days, about 45 days, or a range defined by any two of the foregoing values). In another embodiment, the BTLA-binding agent has an in vivo half-life between about 2 hours and 20 days (e.g., about 5 hours, about 10 hours, about 15 hours, about 20 hours, about 2 days, about 3 days, about 7 days, about 12 days, about 14 days, about 17 days, about 19 days, or a range defined by any two of the foregoing values). In another embodiment, the BTLA-binding agent has an in vivo half-life between about 10 days and about 40 days (e.g., about 10 days, about 13 days, about 16 days, about 18 days, about 20 days, about 23 days, about 26 days, about 29 days, about 30 days, about 33 days, about 37 days, about 38 days, about 39 days, about 40 days, or a range defined by any two of the foregoing values).

[0075] The BTLA-binding agent may be administered alone or in combination with other drugs. For example, the BTLA-binding agent can be administered in combination with other agents for the treatment or prevention of the diseases disclosed herein, such as other agents antiinflammatory or immunosuppressive agents. In this respect, for example, the BTLA-binding agent can be used in combination with at least one other agent including, for example, any antiinflammatory agent known in the art, glucocorticoids, small molecule immunosuppressive agents, vaccines, biological therapies (e.g., other monoclonal antibodies, viruses, gene therapy, and adoptive T-cell transfer), and / or surgery. When the inventive method treats an infectious disease, the BTLA-binding agent can be administered in combination with at least one antibacterial agent or at least one anti-viral agent. In this respect, the anti-bacterial agent can be any suitable antibiotic known in the art. The anti-viral agent can be any vaccine of any suitable type that specifically targets a particular virus (e.g., live-attenuated vaccines, subunit vaccines, recombinant vector vaccines) and any small molecule anti-viral therapies (e.g., viral replication inhibitors and nucleoside analogs).Nucleic Acids

[0100] The invention also provides one or more nucleic acids that encode the immunoglobulin heavy chain polypeptide, the immunoglobulin light chain polypeptide, and the BTLA-binding agent provided herein.

[0101] The term “nucleic acid sequence” is intended to encompass a polymer of DNA or RNA, i.e., a polynucleotide, which can be single- stranded or double-stranded and which can contain non-natural or altered nucleotides. The terms “nucleic acid” and “polynucleotide” as used herein refer to a polymeric form of nucleotides of any length, either ribonucleotides (RNA) or deoxyribonucleotides (DNA). These terms refer to the primary structure of the molecule, and thus include double- and single-stranded DNA, and double- and single-stranded RNA. The terms include, as equivalents, analogs of either RNA or DNA made from nucleotide analogs and modified polynucleotides such as, though not limited to, methylated and / or capped polynucleotides. Nucleic acids are typically linked via phosphate bonds to form nucleic acid sequences or polynucleotides, though many other linkages are known in the art (e.g., phosphorothioates, boranophosphates, and the like).

[0102] The nucleic acid encoding the immunoglobulin heavy chain polypeptide, the immunoglobulin light chain polypeptide, or the BTLA-binding agent can be part of a vector. The vector can be, for example, a plasmid, episome, cosmid, viral vector (e.g., retroviral or adenoviral), or phage. Suitable vectors and methods of vector preparation are well known in the art (see, e.g., Sambrook et al., Molecular Cloning, a Laboratory Manual, 3rd edition, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (2001), and Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates and John Wiley & Sons, New York, N.Y. (1994)).

[0103] The vector typically comprises expression control sequences, such as a promoter, enhancer, polyadenylation signal, transcription terminator, signal peptide (e.g., the osteonectin signal peptide), internal ribosome entry site (IRES), and the like, that provide for the expression of the coding sequence in a host cell. Exemplary expression control sequences are known in the art and described in, for example, Goeddel, Gene Expression Technology: Methods in Enzymology, Vol. 185, Academic Press, San Diego, Calif. (1990).

[0104] A large number of promoters, including constitutive, inducible, and repressible promoters, from a variety of different sources are well known in the art. Representative sources of promoters include for example, virus, mammal, insect, plant, yeast, and bacteria, and suitable promoters from these sources are readily available, or can be made synthetically, based on sequences publicly available, for example, from depositories such as the ATCC as well as other commercial or individual sources. Promoters can be unidirectional (i.e., initiate transcription in one direction) or bi-directional (i.e., initiate transcription in either a 3’ or 5’ direction). Nonlimiting examples of promoters include, for example, the T7 bacterial expression system, pBAD (araA) bacterial expression system, the cytomegalovirus (CMV) promoter, the SV40 promoter, the RSV promoter. Inducible promoters include, for example, the Tet system (U.S. Patents 5,464,758 and 5,814,618), the Ecdysone inducible system (No et al., Proc. Natl. Acad. Sci., 93: 3346-3351 (1996)), the T-REX™ system (Invitrogen, Carlsbad, CA), LACSWITCH™ system (Stratagene, San Diego, CA), and the Cre-ERT tamoxifen inducible recombinase system (Indra et al., Nuc. Acid. Res., 27: 4324-4327 (1999); Nuc. Acid. Res., 28: e99 (2000); U.S. Patent 7,112,715; and Kramer & Fussenegger, Methods Mol. Biol., 308: 123-144 (2005)).

[0105] The term “enhancer” as used herein, refers to a DNA sequence that increases transcription of, for example, a nucleic acid sequence to which it is operably linked. Enhancers can be located many kilobases away from the coding region of the nucleic acid sequence and can mediate the binding of regulatory factors, patterns of DNA methylation, or changes in DNA structure. A large number of enhancers from a variety of different sources are well known in the art and are available as or within cloned polynucleotides (from, e.g., depositories such as the ATCC as well as other commercial or individual sources). A number of polynucleotides comprising promoters (such as the commonly-used CMV promoter) also comprise enhancer sequences. Enhancers can be located upstream, within, or downstream of coding sequences.

[0106] The vector also can comprise a “selectable marker gene.” The term “selectable marker gene,” as used herein, refers to a nucleic acid sequence that allow cells expressing the nucleic acid sequence to be specifically selected for or against, in the presence of a corresponding selective agent. Suitable selectable marker genes are known in the art and described in, e.g., International Patent Application Publications WO 1992 / 008796 and WO 1994 / 028143; Wigler et al., Proc. Natl. Acad. Set. USA, 77'. 3567-3570 (1980); O'Hare et al., Proc. Natl. Acad. Set. USA, 78: 1527-1531 (1981); Mulligan & Berg, Proc. Natl. Acad. Set. USA, 78: 2072-2076 (1981); Colberre-Garapin et al., J. Mol. Biol., 150: 1-14 (1981); Santerre et al., Gene, 30: 147-156 (1984); Kent et al., Science, 237: 901-903 (1987); Wigler et al., Cell, 11: 223- 232 (1977); Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA, 48: 2026-2034 (1962); Lowy et al., Cell, 22: 817-823 (1980); and U.S. Patents 5,122,464 and 5,770,359.

[0107] In some embodiments, the vector is an “episomal expression vector” or “episome,” which is able to replicate in a host cell, and persists as an extrachromosomal segment of DNA within the host cell in the presence of appropriate selective pressure (see, e.g., Conese et al., Gene Therapy, 11: 1735-1742 (2004)). Representative commercially available episomal expression vectors include, but are not limited to, episomal plasmids that utilize Epstein Barr Nuclear Antigen 1 (EBNA1) and the Epstein Barr Virus (EBV) origin of replication (oriP). The vectors pREP4, pCEP4, pREP7, and pcDNA3.1 from Invitrogen (Carlsbad, CA) and pBK-CMV from Stratagene (La Jolla, CA) represent non-limiting examples of an episomal vector that uses T-antigen and the SV40 origin of replication in lieu of EBNA1 and oriP.

[0108] Other suitable vectors include integrating expression vectors, which may randomly integrate into the host cell’s DNA, or may include a recombination site to enable the specific recombination between the expression vector and the host cell’s chromosome. Such integrating expression vectors may utilize the endogenous expression control sequences of the host cell’s chromosomes to effect expression of the desired protein. Examples of vectors that integrate in a site specific manner include, for example, components of the flp-in system from Invitrogen (Carlsbad, CA) (e.g., pcDNA™5 / FRT), or the cre-lox system, such as can be found in the pExchange-6 Core Vectors from Stratagene (La Jolla, CA). Examples of vectors that randomly integrate into host cell chromosomes include, for example, pcDNA3.1 (when introduced in the absence of T-antigen) from Life Technologies (Carlsbad, CA), UCOE from Millipore (Billerica, MA), and pCI or pFNIOA (ACT) FLEXI™ from Promega (Madison, WI).

[0109] Viral vectors also can be used. Representative commercially available viral expression vectors include, but are not limited to, the adenovirus-based Per.C6 system available from Crucell, Inc. (Leiden, The Netherlands), the lentiviral-based pLPl from Invitrogen (Carlsbad, CA), and the retroviral vectors pFB-ERV plus pCFB-EGSH from Stratagene (La Jolla, CA).

[0110] Nucleic acid sequences encoding the inventive amino acid sequences can be provided to a cell on the same vector (i.e., in cis). A unidirectional promoter can be used to control expression of each nucleic acid sequence. In another embodiment, a combination of bidirectional and unidirectional promoters can be used to control expression of multiple nucleic acid sequences. Nucleic acid sequences encoding the inventive amino acid sequences alternatively can be provided to the population of cells on separate vectors (i.e., in trans). Each of the nucleic acid sequences in each of the separate vectors can comprise the same or different expression control sequences. The separate vectors can be provided to cells simultaneously or sequentially[OUl] The vector(s) comprising the nucleic acid(s) encoding the inventive amino acid sequences can be introduced into a host cell that is capable of expressing the polypeptides encoded thereby, including any suitable prokaryotic or eukaryotic cell. As such, the invention provides an isolated cell comprising the inventive vector. Preferred host cells are those that canbe easily and reliably grown, have reasonably fast growth rates, have well characterized expression systems, and can be transformed or transfected easily and efficiently.

[0112] Examples of suitable prokaryotic cells include, but are not limited to, cells from the genera Bacillus (such as Bacillus sublilis and Bacillus brevis), Escherichia (such as E. coll), Pseudomonas, Streptomyces, Salmonella, and Erwinia. Particularly useful prokaryotic cells include the various strains of Escherichia coli (e.g., K12, HB101 (ATCC No. 33694), DH5a, DH10, MC1061 (ATCC No. 53338), and CC102).

[0113] In some embodiments, the vector is introduced into a eukaryotic cell. Suitable eukaryotic cells are known in the art and include, for example, yeast cells, insect cells, and mammalian cells. Examples of suitable yeast cells include those from the genera Kluyveromyces, Pichia, Rhino-sporidium, Saccharomyces, and Schizosaccharomyces . Preferred yeast cells include, for example, Saccharomyces cerivisae and Pichia pastoris.

[0114] Suitable insect cells are described in, for example, Kitts et al., Biotechniques, 14'. 810- 817 (1993); Lucklow, Curr. Opin. Biotechnol., 4'. 564-572 (1993); and Lucklow et al., J. Virol., 67 4566-4579 (1993). Preferred insect cells include Sf-9 and HI5 (Invitrogen, Carlsbad, CA).

[0115] In some embodiments, mammalian cells are utilized in the invention. A number of suitable mammalian host cells are known in the art, and many are available from the American Type Culture Collection (ATCC, Manassas, VA). Examples of suitable mammalian cells include, but are not limited to, Chinese hamster ovary cells (CHO) (e.g., CHO-K1 cells, ATCC No. CCL61), CHO DHFR-cells (Urlaub et al., Proc. Natl. Acad. Sci. USA, 97'. 4216-4220 (1980)), human embryonic kidney (HEK) 293 or 293T cells (ATCC No. CRL1573), and 3T3 cells (ATCC No. CCL92). Other suitable mammalian cell lines are the monkey COS-1 (ATCC No. CRL1650) and COS-7 cell lines (ATCC No. CRL1651), as well as the CV-1 cell line (ATCC No. CCL70). Further exemplary mammalian host cells include primate cell lines and rodent cell lines, including transformed cell lines. Normal diploid cells, cell strains derived from in vitro culture of primary tissue, as well as primary explants, are also suitable. Other suitable mammalian cell lines include, but are not limited to, mouse neuroblastoma N2A cells, HeLa, mouse L-929 cells, and BHK or HaK hamster cell lines, all of which are available from the ATCC. Methods for selecting suitable mammalian host cells and methods for transformation, culture, amplification, screening, and purification of cells are known in the art.

[0116] In one embodiment, the mammalian cell is a human cell. For example, the mammalian cell can be a human lymphoid or lymphoid derived cell line, such as a cell line of pre-B lymphocyte origin. Examples of human lymphoid cells lines include, without limitation, RAMOS (CRL-1596), Daudi (CCL-213), EB-3 (CCL-85), DT40 (CRL-2111), 18-81 (Jack et al., Proc. Natl. Acad. Sci. USA, 85: 1581-1585 (1988)), Raji cells (CCL-86), PER.C6 cells (Crucell Holland B.V., Leiden, The Netherlands), and derivatives thereof.

[0117] A nucleic acid sequence encoding the inventive amino acid sequence may be introduced into a cell by any suitable method, such as by “transfection,” “transformation,” or “transduction.” “Transfection,” “transformation,” or “transduction,” as used herein, refer to the introduction of one or more exogenous polynucleotides into a host cell by using physical or chemical methods. Many suitable techniques are known in the art and include, for example, calcium phosphate DNA co-preci pitati on (see, e.g., Murray E.J. (ed ), Methods in Molecular Biology, Vol. 7, Gene Transfer and Expression Protocols, Humana Press (1991)); DEAE- dextran; electroporation; cationic liposome-mediated transfection; tungsten particle-facilitated microparticle bombardment (Johnston, Nature, 346: 776-777 (1990)); and strontium phosphate DNA co-precipitation (Brash et al., Mol. Cell Biol., 7: 2031-2034 (1987)). Phage or viral vectors can be introduced into host cells, after growth of infectious particles in suitable packaging cells, many of which are commercially available.

[0118] The nucleic acids and cells can be used for any purpose, such as for the manufacture of the BTLA-binding agent described herein. In this respect, the invention provides a method of preparing the BTLA-binding agent comprising culturing a cell comprising a nucleic acid encoding the heavy and / or light immunoglobulin polypeptides of the BTLA-binding agent. Phrased differently, the method comprises expressing a nucleic acid encoding the immunoglobulin heavy and / or light chains of the BTLA-binding agent in a cell (e.g., an in vitro cell, such as any of the cell lines discussed herein including CHO and CHO-K1 cells). It will be appreciated that the immunoglobulin heavy and light chains can be expressed from a single nucleic acid in a given cell, or the immunoglobulin heavy and light chains can be expressed from separate nucleic acids in the same cell. The method can further comprise harvesting and / or purifying the BTLA-binding agent from the cell or cell culture media using known techniques.

[0119] The following examples further illustrate the invention but, of course, should not be construed as in any way limiting its scope.EXAMPLES

[0120] Table 2 provides Examples of BTLA binding agents (e.g., antibodies or antibody fragments) comprising immunoglobulin heavy chain variable regions of SEQ ID NOs: 1-15 and light chain variable regions of SEQ ID NOs: 16-25.Table 2

[0121] For antibodies or antibody fragments in Table 2, Kabat numbered CDRs are as follows: CDRH1 is located at positions 31-35 of the respective VH sequence; CDRH2 is located at positions 50-66 of the respective VH sequence; CDRH3 is located at positions 99-106 of the respective VH sequence; CDRL1 is located at positions 24-34 of the respective VL sequence; CDRL2 is location at positions 50-56 of the respective VL sequence; and CDRL3 is located at positions 89-97 of the respective VL sequence. BTLA binding agents having the pairing of heavy and light chain variable regions set forth in Table 2, or at least the CDRs thereof, provide specific embodiments of the disclosure. Additional pairings of the heavy and light chain variable regions of Table 2, or at least the CDRs thereof, would provide still other BTLA binding agents, and are contemplated as being within the scope of the disclosure.

[0122] Table 3 provides Examples of BTLA binding agents (e.g., antibodies or antibody fragments) comprising immunoglobulin heavy chain variable regions of SEQ ID NOs: 43-156 and light chain variable regions of SEQ ID NOs: 157-192.Table 3

[0123] For the antibodies or antibody fragements in Table 3, the Kabat numbered CDR regions are as follows: CDRH1 is located at positions 31-35 of the respective VH sequence; CDRH2 is located at positions 50-66 of the respective VH sequence, except for the antibodies marked with *, in which CDRH2 is located a positions 50-67 of the respective VH sequence; CDRH3 is located at positions 99-113 of the respective VH sequence, except for the antibodies marked with f, in which CDRH3 is located at positions 100-114; CDRL1 is located at positions 24-34 of the respective VL sequence; CDRL2 is location at positions 50-56 of the respective VL sequence; CDRL3 is located at positions 89-97 of the respective VL sequence. BTLA binding agents having the pairing of heavy and light chain variable regions set forth in Table 3, or at least the CDRs thereof, provide specific embodiments of the disclosure. Additional pairings of the heavy and light chain variable regions of Table 3, or at least the CDRs thereof, would provide still other BTLA binding agents, and are contemplated as being within the scope of the disclosure.

[0124] In the following examples, the antibodies referenced are as follows:EXAMPLES

[0125] The following example illustrates the effect of a BTLA agonist as provided herein on dendritic cell function and maturation.

[0126] As illustrated in Fig. 1, extracellular signals (e.g., PAMPs or DAMPs, pathogens, cytokines, toll-like receptor agonists such as lipopolysaccharide (LPS)) cause immature dendritic cells (DCs) to mature with significant changes on surface proteins, intracellular pathways, and metabolic activity. During this process, DCs lose adhesive structures, reorganize the cytoskeleton, and increase motility. Mature DCs have decreased endocytic activity and increased expression of MHC-II and co-stimulatory molecules. Mature DC also express higher levels CCR7 and secrete cytokines needed for T-cell activation. BTLA is highly expressed on mature dendritic cells (Fig. 4).

[0127] Peripheral blood mononuclear cells (PBMCs) from atopic dermatitis patients were incubated with the 6G3 BTLA agonist antibody provided herein, and were analyzed three days later for T-cell proliferation and cytokine secretion. The results demonstrate that the BTLA agonist inhibited T cell proliferation (Fig. 2A and 2B) and Thl, Th2,Thl7, and Th22 cytokine secretion in the atopic dermatitis patient-derived PBMCs (Figs. 3A-3D).

[0128] The BTLA agonist also inhibits DC maturation, reduces antigen presentation, and reduces co-stimulatory molecules. Dendritic cells were stimulated with LPS with and without incubation with agonist antibody 6G3. Isotype antibody served as a control. As shown in Figures 6A and 6B, the BTLA agonist inhibited LPS-stimulated maturation of DCs. The BTLA agonist also reduced antigen presentation (Fig. 6C) and reduced the levelcostimulatory molecules expressed on the DCs (Fig. 6D).

[0129] To examine the effect on regulatory T-cells, allogeneic dendritic cells treated with BTLA agonist 6G3 or isotype antibody (control) were co-cultured with naive CD4+ T-cells for 5 days, and the population of regulatory T-cells analyzed by CD25 and Foxp3 expression. The results are presented in Fig. 7B, and shows that dendritic cells treated with the BTLA agonist induced functional Tregs, which helps restore immune balance. Figure 5 is a schematic illustration of how the BTLA agonist provided herein modulates BTLA expression, reducing the number of mature dendritic cells, and therefore, reduces T-cell proliferation and cytokine secretion, and increases regulatory T-cells (Tregs).

[0130] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.

[0131] The use of the terms “a” and “an” and “the” and “at least one” and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The use of the term “at least one” followed by a list of one or more items (for example, “at least one of A and B”) is to be construed to mean one item selected from the listed items (A or B) or any combination of two or more of the listed items (A and B), unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to,”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.

[0132] Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variationsthereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.

Claims

CLAIMS:

1. A method of modulating dendritic cell maturation, the method comprising administering a BTLA agonist to the patient.

2. A method of treating a condition associated with dendritic cell maturation, or a condition characterized by abnormally high levels of mature dendritic cells as compared to immature dendtric cells, the method comprising administering a BTLA agonist to the patient.

3. A method of selecting a patient for treatment with a BTLA agonist, the method comprising determining the level of mature dendritic cells in a patient or in a biological sample from the patient, and selecting the patient for treatment if the level of mature dendritic cells is elevated as compared to a control.

4. The method of claim 3, wherein determining the level of mature dendritic cells comprises determining a ratio of the number of mature dendritic cells as compared to immature dendritic cells, and selecting the patient for treatment if the ratio is elevated as compared to a control.

5. A method of monitoring the treatment of a patient with a BTLA agonist, the method comprising monitoring the level of mature dendritic cells in a patient or in a biological sample from a patient, wherein a decrease in the level of mature dendritic cells indicates that the patient is responding to the treatment with the BTLA agonist.

6. The method of claim 5, wheren monitoring the level of mature dendritic cells comprises determining a ratio of the number of mature dendritic cells as compared to immature dendritic cells, and a decrease in the ratio of mature dendritic cells to immature dendritic cells indicates that the patient is responding to the treatment with the BTLA agonist.

7. The method of claim 5 or 6, wherein the method comprises comparing the level of mature dendritic cells in a patient or in a biological sample from a patient before administration of a BTLA agonist to the level of mature dendritic cells in the patient or in the biological sample from the patient after administration of a BTLA agonist.

8. The method of any of claims 1-7, wherein the BTLA agonist is a BTLA-binding agent comprising: an immunoglobulin heavy chain variable region comprising:(a) a CDRH1 comprising X1SX2MN (SEQ ID NO: 195), wherein X1is N or T, and X2is W, F, H, G, P, R, K, D, S, L, V, N, or Y(b) a CDRH2 comprising RIYPX1GX2X3DTNYX4GKFK (SEQ ID NO: 196), wherein: X1is absent or A;X2is D, Y, Q, G, L, F, H, S, P, R, or T;X3is G, Y, A, F, S, D, V, T, E, K, or R; andX4is N, V, Q, R, A, F, Y, S, G, P, or T; and(c) a CDRH3 comprising X1SGTFX2X3GNYX4X5YFDV (SEQ ID NO: 197), wherein:X1is K or R;X2is N or D;X3is D, S, F, Y, F, V, S, G, T, R, I, L, or E;X4is R or H; andX5is W, R, F, L, N, Y, P, I, V, A, S, G, R, or K; or comprising the immunoglobulin heavy chain variable region of any one of SEQ ID NOs: 43-156, or at least the CDRs thereof; or an amino acid sequence with at least 90% sequence identity thereto; and an immunoglobulin light chain variable region comprising:(a) a CDRL1 comprising RX1SENIYX2X3LA (SEQ ID NO: 198), whereinX1is A or V;X2is S or N; andX3is H, N, or Y;(b) a CDRL2 comprising X^^AX3(SEQ ID NO: 199), whereinX1is A or N;X2is T or K; andX3is N, L, Q, G, F, V, K, S, R, T, H, or P; and(c) a CDRL3 comprising QX1FX2GPPLT (SEQ ID NO: 200), whereinX1is L or H; andX2is W, F, Y, P, N, V, K, M, L, G, or S; or comprising the immunoglobulin light chain variable region of any of SEQ ID NOs: 157-192, or at least the CDRs thereof; or an amino acid sequence with at least 90% sequence identity thereto; or a BTLA binding agent as set forth in Table 3.

9. The method of claim 8, wherein the immunoglobulin heavy chain polypeptide comprises the sequence: QVQLVQSGAEVKKPGSSVKVSCKASGYX1FSX2SX3MNWVRQAPGQGLEWMGRIYPX4GX5X6DTNYX7GKFKGRVTITADKX8TX9TAYMELX10SLRSEX11TAVX12YX13CAX14SGTF X15X16GNYX17X18YFDVWGKGTTVTVSSA (SEQ ID NO: 193), whereinXIis A or V;X2is N or T;X3is W, F, H, G, P, R, K, D, S, L, V, N, or Y;X4is absent or A;X5is D, Y, Q, G, L, F, H, S, P, R, or T;X6is G, Y, A, F, S, D, V, T, E, K, or R;X7is N, V, Q, R, A, F, Y, S, G, P, or T;X8is S or F;X9is S, T, or N;X10is S or R;XI Iis D or V;X12is absent or Y;X13is Y or F;X14is K or R;X15is N or D;X16is D, S, F, Y, F, V, S, G, T, R, I, L, or E;X17is R or H; andX18is W, R, F, L, N, Y, P, I, V, A, S, G, R, or K.

10. The method of claim 8 or 9, wherein the immunoglobulin heavy chain polypeptide comprises any one of SEQ ID NOs: 43-156, or at least the CDRs thereof; or an amino acid sequence with at least 90% sequence identity thereto.

11. The method of any of claims 8-10, wherein the immunoglobulin light chain polypeptide comprises the sequence: X1IQX2TQSPSSLSASVGDRVTITCRX3SENIYX4X5LAWYQQKX6GKAPKLLIYX7AX8NLA X9GVPSRFSGSGSGTDX1OTLTISSLQPEDFATYYCQX11FX12GPPLTFGGGTKVEIKR (SEQ ID NO: 194), whereinXIis A or D;X2is L or M;X3is A or V;X4is S or N;X5is H, N, or Y;X6is P or Q;X7is A or N;X8is T or K;X9is N, L, Q, G, F, V, K, S, R, T, H, or P;X10is F or Y;XI Iis L or H;X12is W, F, Y, P, N, V, K, M, L, G, S.

12. The method of any of claims 8-11, wherein the immunoglobulin light chain polypeptide comprises any of SEQ ID NOs: 157-192, or at least the CDRs thereof; or an amino acid sequence with at least 90% sequence identity thereto.

13. The method of any of claims 8-12 comprising(a) a CDRH1 comprising SEQ ID NO: 201;(b) a CDRH2 comprising SEQ ID NO: 202;(c) a CDRH3 comprising SEQ ID NO: 203;(d) a CDRL1 comprising SEQ ID NO: 204;(e) a CDRL2 comprising SEQ ID NO: 205; and(f) a CDRL3 comprising SEQ ID NO: 206.

14. The method of any of claims 8-13 comprising an immunoglobulin heavy chain variable region of SEQ ID NO: 144, or at least the CDRs thereof; and an immunoglobulin light chain variable region of SEQ ID NO: 174, or at least the CDRs thereof; or comprising an immunoglobulin heavy chain variable region with 90% or more sequence identity to SEQ ID NO: 144, and an immunoglobulin light chain variable region of SEQ ID NO: 174.

15. The method of any of claims 1-7, wherein the BTLA agonist is a binding agent comprising: a heavy chain immunoglobulin variable region comprising:(a) a CDRH1 comprising Asp Tyr Thr He His (SEQ ID NO: 27),(b) a CDRH2 comprising Trp He Tyr Pro Gly Ser Gly Asn Thr Lys Tyr Asn Asp Lys Phe Lys Xaa (SEQ ID NO: 30), wherein Xaa is aspartic acid (Asp) or valine (Vai);(c) a CDRH3 comprising Arg Xaal Xaa2 Tyr Xaa3 Met Xaa4 Tyr (SEQ ID NO: 32), wherein:Xaal is asparagine (Asn) or serine (Ser),Xaa2 is tyrosine (Tyr) or histidine (His),Xaa3 is alanine (Ala) or valine (Vai), andXaa4 is glutamic acid (Glu) or aspartic acid (Asp); or comprising a heavy chain variable region comprising any one of SEQ ID NOs: 1-15, 207, 208, 217, or 218, or at least the CDRs thereof, or an amino acid sequence with at least 90% sequence identity thereto; and a light chain immunoglobulin variable region comprising:(a) a CDRL1 comprising Lys Ala Ser Gin Asn Vai Phe Thr Asn Vai Ala (SEQ ID NO: 36);(b) a CDRL2 comprising Ser Ala Ser Tyr Arg Xaa Ser (SEQ ID NO: 39), wherein Xaa is tyrosine (Tyr) or serine (Ser); and(c) a CDRL3 comprising Gin Gin Tyr Xaal Xaa2 Tyr Pro Tyr Thr (SEQ ID NO: 41), wherein:Xaal is serine (Ser) or asparagine (Asn), andXaa2 is threonine (Thr) or serine (Ser); or comprising a light chain variable region comprising any one of SEQ ID NOs: 16-25, 209, 210, 219, or 220, or at least the CDRs thereof, or an amino acid sequence with at least 90% sequence identity thereto; or a BTLA binding agent as set forth in Table 2.

16. The method of claim 15, wherein the CDRH2 comprises SEQ ID NO: 31; and CDRH3 comprises SEQ ID NO: 33 or 34.

17. The method of claim 15 or 16, wherein the CDRL2 comprises SEQ ID NO: 40; and the CDRL3 comprises SEQ ID NO: 42.

18. The method of any of claims 15-17, wherein the binding agent comprises a heavy chain variable region comprising the amino acid sequence Gin Vai Gin Leu Vai Gin Ser Gly Ala Glu Vai Lys Lys Pro Gly Ala Ser Vai Lys Vai Ser Cys Lys Ala Ser Gly Xaal Thr Xaa2 Thr Asp Tyr Thr He His Trp Vai Arg Gin Ala Pro Gly Gin Arg Leu Glu Trp Met Gly Trp He Tyr Pro Gly Ser Gly Asn Thr Lys Tyr Asn Asp Lys Phe Lys Xaa3 Arg Vai Thr He Thr Xaa4 Asp Xaa5 Ser Xaa6 Xaa7 Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Vai Tyr Xaa8 Cys Ala Arg Arg Xaa9 XaalO Tyr Xaal 1 Met Xaal2 Tyr Trp Gly Gin Gly Thr Thr Vai Thr Vai Ser Ser Ala (SEQ ID NO: 26), wherein:Xaal is phenylalanine (Phe) or tyrosine (Tyr),Xaa2 is phenylalanine (Phe) or leucine (Leu),Xaa3 is aspartic acid (Asp) or valine (Vai),Xaa4 is alanine (Ala) or arginine (Arg),Xaa5 is lysine (Lys) or threonine (Thr),Xaa6 is alanine (Ala) or serine (Ser),Xaa7 is serine (Ser) or threonine (Thr),Xaa8 is tyrosine (Tyr) or phenylalanine (Phe),Xaa9 is asparagine (Asn) or serine (Ser),XaalO is tyrosine (Tyr) or histidine (His),Xaal 1 is alanine (Ala) or valine (Vai), andXaal2 is glutamic acid (Glu) or aspartic acid (Asp).

19. The method of any of claims 15-18, wherein the binding agent comprises a heavy chain variable region comprising any one of SEQ ID NOs: 1-15, 207, 208, 217, or 218, or at least the CDRs thereof, or an amino acid sequence with at least 90% sequence identity thereto.

20. The method of any of claims 15-19, wherein the binding agent comprises a light chain variable region comprising the amino acid sequence Asp He Vai Met Thr Gin Ser Pro Asp Ser Leu Ala Vai Ser Leu Gly Glu Arg Ala Thr He Asn Cys Lys Ala Ser Gin Asn Vai Phe Thr Asn Vai Ala Trp Tyr Gin Gin Lys Pro Gly Gin Xaa Pro Lys Xaa Leu lie Tyr Ser Ala Ser Tyr Arg Xaa Ser Gly Vai Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr He Ser Ser Leu Gin Ala Glu Asp Vai Ala Vai Tyr Xaa Cys Gin Gin Tyr Xaa Xaa Tyr Pro Tyr Thr Phe Gly Gin Gly Thr Lys Leu Glu He Lys Arg (SEQ ID NO: 35), whereinXaal is serine (Ser) or proline (Pro),Xaa2 is proline (Pro) or leucine (Leu),Xaa3 is tyrosine (Tyr) or serine (Ser),Xaa4 is tyrosine (Tyr) or phenylalanine (Phe),Xaa5 is serine (Ser) or asparagine (Asn), andXaa6 is threonine (Thr) or serine (Ser).

21. The method of any of claims 15-20, wherein the binding agent comprises a light chain variable region comprising any one of SEQ ID NOs: 16-25, 209, 210, 219, or 220, or at least the CDRs thereof, or an amino acid sequence with at least 90% sequence identity thereto.

22. The method of any of claims 8-21, wherein the BTLA binding agent is an antibody, an antibody conjugate, or an antigen-binding fragment thereof, optionally an IgGl or IgG4 antibody.

23. The method of claim 22, wherein the BTLA binding agent is a F(ab’)2 fragment, a Fab’ fragment, a Fab fragment, a Fv fragment, a scFv fragment, a dsFv fragment, a dAb fragment, or a single chain binding polypeptide.

24. The method of any of claims 1-23, wherein the biological sample is blood, plasma, serum, or tissue sample or fraction thereof.

25. The method of claim 3 or 4, or any claim depending therefrom, wherein the control is the level of mature dendritic cells in a non-diseased biological sample from the same patient; or the level of mature dendritic cells of another normal, non-diseased subject of the same type; or a reference level of mature dendritic cells established by the statistical analysis of the level of dendritic in a population of such normal, non-diseased subjects.

26. The method of any of claims 1-25, further comprising a step of administering a BTLA agonist to the subject.

27. A BTLA agonist for use in the method of any of claims 1-26.

28. The BTLA agonist of claim 27, wherein the BTLA agonist is a BTLA binding agent comprising an immunoglobulin heavy chain variable region of SEQ ID NO: 144, or at least the CDRs thereof; and an immunoglobulin heavy light chain variable region of SEQ ID NO: 174, or at least the CDRs thereof; or comprises an immunoglobulin heavy chain variable region with 90% or more sequence identity to SEQ ID NO: 144, and an immunoglobulin light chain variable region of SEQ ID NO: 174.

29. The method of any of claims 39-41, wherein the disorder is an autoimmune or inflammatory disease.

30. The method of any of claims 39-41, wherein the disease is rheumatoid arthritis, graft vs host disease, psoriasis, or inflammatory bowel disease.

Citation Information

Patent Citations

  • Methods of generating libraries and uses thereof

    US20090093024A1

  • Methods of generating libraries and uses thereof

    US20110287485A1

  • Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents

    US4828981A

  • Method for dominant selection in eucaryotic cells

    US5122464A

  • Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters

    US5464758A